

N- (MORPHOLIN-2-YL) METHYL ACETAMIDE DERIVATIVES AS CCR-3 ANTAGONISTS USEFUL  
IN THE TREATMENT OF INFLAMMATORY DISEASES

Novel Compounds

This invention relates to novel compounds, processes for their preparation, pharmaceutical formulations containing them and their use in  
5 therapy.

Inflammation is a primary response to tissue injury or microbial invasion and is characterised by leukocyte adhesion to the endothelium, diapedesis and activation within the tissue. Leukocyte activation can result in the generation of toxic oxygen species (such as superoxide anion), and the release of granule  
10 products (such as peroxidases and proteases). Circulating leukocytes include neutrophils, eosinophils, basophils, monocytes and lymphocytes. Different forms of inflammation involve different types of infiltrating leukocytes, the particular profile being regulated by the profile of adhesion molecule, cytokine and chemotactic factor expression within the tissue.

15 The primary function of leukocytes is to defend the host from invading organisms, such as bacteria and parasites. Once a tissue is injured or infected, a series of events occurs which causes the local recruitment of leukocytes from the circulation into the affected tissue. Leukocyte recruitment is controlled to allow for the orderly destruction and phagocytosis of foreign or dead cells,  
20 followed by tissue repair and resolution of the inflammatory infiltrate. However in chronic inflammatory states, recruitment is often inappropriate, resolution is not adequately controlled and the inflammatory reaction causes tissue destruction.

There is increasing evidence that the bronchial inflammation which is characteristic of asthma represents a specialised form of cell-mediated immunity,  
25 in which cytokine products, such as IL-4 and IL-5 released by T-helper 2 (Th2) lymphocytes, orchestrate the accumulation and activation of granulocytes, in particular eosinophils and to a lesser extent basophils. Through the release of cytotoxic basic proteins, pro-inflammatory mediators and oxygen radicals, eosinophils generate mucosal damage and initiate mechanisms that underlie  
30 bronchial hyperreactivity. Therefore, blocking the recruitment and activation of Th2 cells and eosinophils is likely to have anti-inflammatory properties in asthma. In addition, eosinophils have been implicated in other disease types such as rhinitis, eczema, irritable bowel syndrome and parasitic infections.

Chemokines are a large family of small proteins which are involved in  
35 trafficking and recruitment of leukocytes (for review see Luster, New Eng. J. Med., 338, 436-445 (1998)). They are released by a wide variety of cells and act to attract and activate various cell types, including eosinophils, basophils, neutrophils, macrophages, T and B lymphocytes. There are two major families of chemokines, CXC- ( $\alpha$ ) and CC- ( $\beta$ ) chemokines, classified according to the  
40 spacing of two conserved cysteine residues near to the amino terminus of the

chemokine proteins. Chemokines bind to specific cell surface receptors belonging to the family of G-protein-coupled seven transmembrane-domain proteins (for review see Luster, 1998). Activation of chemokine receptors results in, amongst other responses, an increase in intracellular calcium, changes in cell shape, increased expression of cellular adhesion molecules, degranulation and promotion of cell migration (chemotaxis).

To date a number of CC chemokine receptors have been identified and of particular importance to the current invention is the CC-chemokine receptor-3 (CCR-3), which is predominantly expressed on eosinophils, and also on basophils, mast cells and Th2 cells. Chemokines that act at CCR-3, such as RANTES, MCP-3 and MCP-4, are known to recruit and activate eosinophils. Of particular interest are eotaxin and eotaxin-2, which specifically bind to CCR-3. The localization and function of CCR-3 chemokines indicate that they play a central role in the development of allergic diseases such as asthma. Thus, CCR-3 is specifically expressed on all the major cell types involved in inflammatory allergic responses. Chemokines that act at CCR-3 are generated in response to inflammatory stimuli and act to recruit these cell types to sites of inflammation, where they cause their activation (e.g. Griffiths et al., J. Exp. Med., 179, 881-887 (1994), Lloyd et al., J. Exp. Med., 191, 265-273 (2000)). In addition, anti-CCR-3 monoclonal antibodies completely inhibit eotaxin interaction with eosinophils (Heath, H. et al., J. Clin. Invest. 99 (2), 178-184 (1997)), while an antibody for the CCR-3 specific chemokine, eotaxin, reduced both bronchial hyperreactivity and lung eosinophilia in an animal model of asthma (Gonzalo et al., J. Exp. Med., 188, 157-167 (1998)). Thus, many lines of evidence indicate that antagonists at the CCR-3 receptor are very likely to be of therapeutic use for the treatment of a range of inflammatory conditions.

In addition to a key role in inflammatory disorders, chemokines and their receptors also play a role in infectious disease. Mammalian cytomegaloviruses, herpes viruses and pox viruses express chemokine receptor homologues, which can be activated by human CC chemokines such as RANTES and MCP-3 receptors (for review see Wells and Schwartz, Curr. Opin. Biotech., 8, 741-748, 1997). In addition, human chemokine receptors, such as CXCR-4, CCR-5 and CCR-3, can act as co-receptors for the infection of mammalian cells by microbes such as human immunodeficiency viruses (HIV). Thus, chemokine receptor antagonists, including CCR-3 antagonists, may be useful in blocking infection of CCR-3 expressing cells by HIV or in preventing the manipulation of immune cellular responses by viruses such as cytomegaloviruses.

International Patent Application publication number WO 01/24786 (Shionogi & Co. Ltd.) discloses certain aryl and heteroaryl derivatives for treating diabetes. WO 00/69830 (Torrey Pines Institute for Molecular Studies) discloses


- certain diazacyclic compounds, and libraries containing them, for biological screening. WO 00/18767 (Neurogen Corporation) discloses certain piperazine derivatives as dopamine D4 receptor antagonists. United States Patent 6,031,097 and WO 99/21848 (Neurogen Corporation) discloses certain
- 5 aminoisoquinoline derivatives as dopamine receptor ligands. WO 99/06384 (Recordati Industria Chimica) discloses piperazine derivatives useful for the treatment of neuromuscular dysfunction of the lower urinary tract. WO 98/56771 (Schering Aktiengesellschaft) discloses certain piperazine derivatives as anti-inflammatory agents. WO 97/47601 (Yoshitomi Pharmaceutical Industries Ltd.)
- 10 discloses certain fused heterocyclic compounds as dopamine D-receptor blocking agents. WO 96/39386 (Schering Corporation) discloses certain piperidine derivatives as neurokinin antagonists. WO 96/02534 (Byk Gulden Lomberg Chemische Fabrik GmbH) discloses certain piperazine thiopyridines useful for controlling helicobacter bacteria. WO 95/32196 (Merck Sharp &
- 15 Dohme Limited) discloses certain piperazine, piperidine, and tetrahydropyridine derivatives as 5-HT1D-alpha antagonists. United States Patent 5,389,635 (E.I. Du Pont de Nemours and Company) discloses certain substituted imadazoles as angiotensin-II antagonists. European Patent Application publication number 0 306 440 (Schering Aktiengesellschaft) discloses certain imidazole derivatives as
- 20 cardiovascular agents.

A novel group of compounds has now been found which are CCR-3 antagonists. These compounds block the migration/chemotaxis of eosinophils and thus possess anti-inflammatory properties. These compounds are therefore of potential therapeutic benefit, especially in providing protection from eosinophil,

25 basophil mast cell and Th2-cell-induced tissue damage in diseases where such cell types are implicated, particularly allergic diseases, including but not limited to bronchial asthma, allergic rhinitis and atopic dermatitis.

Thus, according to one aspect of the invention, there are provided compounds of formula (I):

30



wherein:

R<sup>1</sup> represents substituted or unsubstituted heterocyclyl;

Y represents  $-(CR_{na}R_{nb})_n-$ ;

$R_{na}$  and  $R_{nb}$  are each independently hydrogen or  $C_{1-6}$ alkyl;

n is an integer from 1 to 5;

$R^2$  represents unsubstituted or substituted aryl or unsubstituted or  
5 substituted heteroaryl;

$R^3$  represents hydrogen or  $C_{1-6}$ alkyl;

and salts and solvates thereof;

with the proviso that the following compound is excluded;

N-[[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl]-2-(1,1-dioxidothiomorpholin-4-  
10 yl)acetamide.

Examples of the heterocyclyl group,  $R^1$ , include uracilyl, pyrandionyl, piperaziny, hydantoinyl and piperidinyl.

When  $R^1$  is substituted heterocyclyl, suitable substituents include aminocarbonyl,  $C_{3-8}$ cycloalkylaminocarbonyl,  $C_{1-6}$ alkylsulphonylamino,  $C_{1-6}$ alkylcarbonyl,  $C_{3-8}$ cycloalkylcarbonyl, mono- and di- $(C_{1-6}$ alkyl)aminocarbonyl,  $C_{1-6}$ alkoxycarbonyl,  $C_{1-6}$ alkylsulphonyl,  $C_{1-6}$ alkoxy $C_{1-6}$ alkyl,  $C_{1-6}$ alkylcarbonylamino, and  $C_{1-6}$ alkyl.


Suitably,  $R^1$  is unsubstituted or substituted pyrandionyl, unsubstituted or substituted uracilyl, unsubstituted or substituted piperidinyl, unsubstituted or  
20 substituted hydantoinyl, or unsubstituted or substituted piperaziny.


When  $R^1$  is substituted piperidinyl, suitable substituents include aminocarbonyl,  $C_{1-6}$ alkylsulphonylamino,  $C_{1-6}$ alkylcarbonylamino,  $C_{3-8}$ cycloalkylcarbonyl, mono- and di- $(C_{1-6}$ alkyl)aminocarbonyl,  $C_{1-6}$ alkylcarbonyl,  $C_{1-6}$ alkoxycarbonyl,  $C_{1-6}$ alkylcarbonylamino, cycloalkylaminocarbonyl, and  $C_{1-6}$ alkylsulphonyl.  
25

When  $R^1$  is substituted uracilyl, suitable substituents include  $C_{1-6}$ alkyl.

More suitably,  $R^1$  is pyran-3,4-dion-6-yl, 4-methyluracil-6-yl, 1-(methylcarbonyl)piperidin-4-yl, piperidin-4-yl, 1-(aminocarbonyl)piperidin-4-yl, 1-(cyclopropylaminocarbonyl)piperidin-4-yl, 1-(*tert*-butoxycarbonyl)piperidin-4-yl, 4-(methanesulphonylamino)piperidin-1-yl, 4-(methylcarbonylamino)piperidin-1-yl,  
30 1-(cyclopropylcarbonyl)piperidin-4-yl, 1-(ethylaminocarbonyl)piperidin-4-yl, 1-(*iso*-propylaminocarbonyl)piperidin-4-yl, 1-(*iso*-propylcarbonyl)piperidin-4-yl, 1-(ethoxycarbonyl)piperidin-4-yl, 1-(methoxycarbonyl)piperidin-4-yl, 1-(ethylcarbonyl)piperidin-4-yl, 1-(ethanesulphonyl)piperidin-4-yl, 1-(methylaminocarbonyl)piperidin-4-yl, 1-(methanesulphonyl)piperidin-4-yl, 1-  
35

((diethyl)aminocarbonyl)piperidin-4-yl,





Suitably,  $R_{na}$  and  $R_{nb}$  are both hydrogen.

5 Suitably,  $n$  is 1 or 2.

Suitably,  $R^3$  is hydrogen.

When  $R^2$  is aryl, examples include phenyl.

When  $R^2$  is substituted aryl, suitable substituents include cyano, perhalo $C_{1-6}$ alkyl, amido, halo,  $C_{1-6}$ alkyl,  $C_{1-6}$ alkoxycarbonyl, mono- and di-( $C_{1-6}$ alkyl)aminocarbonyl,  $C_{1-6}$ alkoxy, nitro,  $C_{1-6}$ alkylsulphonyl, hydroxy,  $C_{1-6}$ alkoxy $C_{1-6}$ alkyl,  $C_{1-6}$ alkylthio, mono- and di-( $C_{1-6}$ alkyl)amino, and  $C_{1-6}$ alkylcarbonylamino.

When  $R^2$  is heteroaryl, examples include thiophenyl.

When  $R^2$  is substituted heteroaryl, suitable substituents include cyano, perhalo $C_{1-6}$ alkyl, amido, halo,  $C_{1-6}$ alkyl,  $C_{1-6}$ alkoxycarbonyl, mono- and di-( $C_{1-6}$ alkyl)aminocarbonyl,  $C_{1-6}$ alkoxy, nitro,  $C_{1-6}$ alkylsulphonyl, hydroxy,  $C_{1-6}$ alkoxy $C_{1-6}$ alkyl,  $C_{1-6}$ alkylthio, mono- and di-( $C_{1-6}$ alkyl)amino, and  $C_{1-6}$ alkylcarbonylamino.

Suitably,  $R^2$  is unsubstituted or substituted phenyl or unsubstituted or substituted thiophenyl.

When  $R^2$  is substituted phenyl suitable substituents include halo.

20 More suitably,  $R^2$  is phenyl substituted with chloro.

Preferably,  $R^2$  is 3,4-dichlorophenyl.

Suitable compounds of the invention are Examples 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14, 15, 19, and 20.

Preferred compounds of the invention are Examples 1, 2, 3, 4, 5, 6, 7, 8, 25 9, 10, and 11.


More preferred compounds of the invention are Examples 1, 2, and 3.

Suitable salts of the compounds of formula (I) include physiologically acceptable salts and salts which may not be physiologically acceptable but may be useful in the preparation of compounds of formula (I) and physiologically acceptable salts thereof. If appropriate, acid addition salts may be derived from 30 inorganic or organic acids, for example hydrochlorides, hydrobromides, sulphates, phosphates, acetates, benzoates, citrates, succinates, lactates,

tartrates, fumarates, maleates, 1-hydroxy-2-naphthoates, palmoates, methanesulphonates, formates or trifluoroacetates.

Examples of solvates include hydrates.

There exists a preferred subgroup of compounds of formula (I) being of  
5 formula (I')



wherein;

10  $R^1$  is unsubstituted or substituted heterocyclyl, and;

$R^2$  is phenyl substituted with halo.

Examples of the heterocyclyl group,  $R^1$ , include hydantoinyl, piperazinyl, and piperidinyl.

Suitably,  $R^1$  is unsubstituted hydantoinyl or hydantoinyl substituted with

15  $C_{1-6}$ alkyl, piperazinyl substituted with  $C_{1-6}$ alkyl, unsubstituted piperidinyl or piperidinyl substituted with  $C_{3-8}$ cycloalkylcarbonyl,  $C_{1-6}$ alkylcarbonyl,  $C_{1-6}$ alkoxycarbonyl,  $C_{1-6}$ alkylsulphonyl, mono- or di- $(C_{1-6}$ alkyl)aminocarbonyl, amido,  $C_{3-8}$ cycloalkylaminocarbonyl,  $C_{1-6}$ alkylsulphonylamino, or  $C_{1-6}$ alkylcarbonylamino.

Preferably,  $R^1$  is 1-(cyclopropylcarbonyl)piperidin-4-yl, 1-  
20 (ethylaminocarbonyl)piperidin-4-yl, 1-(*iso*-propylaminocarbonyl)piperidin-4-yl, 1-(*iso*-propylcarbonyl)piperidin-4-yl, 1-(ethoxycarbonyl)piperidin-4-yl, 1-(methoxycarbonyl)piperidin-4-yl, 1-(ethylcarbonyl)piperidin-4-yl, 1-(ethanesulphonyl)piperidin-4-yl, 1-(methylaminocarbonyl)piperidin-4-yl, 1-(methanesulphonyl)piperidin-4-yl, 1-(diethylaminocarbonyl)piperidin-4-yl, 1-  
25 (methylcarbonyl)piperidin-4-yl, piperidin-4-yl, 1-(amido)piperidin-4-yl, 1-(cyclopropylaminocarbonyl)piperidin-4-yl, 1-(*tert*-butoxycarbonyl)piperidin-4-yl, 1-(methanesulphonylamino)piperidin-4-yl, or 1-(methylcarbonylamino)piperidin-4-yl.

Suitably,  $R^2$  is phenyl substituted with chloro or fluoro.

30 Preferably,  $R^2$  is 3,4-dichlorophenyl.

Suitably, the stereochemistry at the position marked '\*' is (S).

Accordingly, there is provided a compound of formula (I') or a salt or solvate thereof.

Certain of the compounds of formula (I) may contain chiral atoms and/or multiple bonds, and hence may exist in one or more stereoisomeric forms. The present invention encompasses all of the stereoisomers of the compounds of formula (I), including geometric isomers and optical isomers, whether as individual stereoisomers or as mixtures thereof including racemic modifications.

Generally it is preferred that a compound of formula (I) is in the form of a single enantiomer or diastereoisomer.

Certain of the compounds of formula (I) may exist in one of several tautomeric forms. It will be understood that the present invention encompasses all of the tautomers of the compounds of formula (I) whether as individual tautomers or as mixtures thereof.

References to 'aryl' refer to monocyclic and bicyclic carbocyclic aromatic rings, for example naphthyl and phenyl, especially phenyl.

Suitable substituents for any aryl group include 1 to 5, suitably 1 to 3, substituents selected from the list consisting of cyano, perhaloalkyl, amido, halo, alkyl, alkoxycarbonyl, mono- and di-(alkyl)aminocarbonyl, alkoxy, nitro, alkylsulphonyl, hydroxy, alkoxyalkyl, alkylthio, mono- and di-(alkyl)amino, and alkylcarbonylamino.

References to 'heteroaryl' refer to monocyclic heterocyclic aromatic rings containing 1-4 heteroatoms selected from nitrogen, oxygen and sulphur. Examples of heterocyclic aromatic rings include thiophenyl.

Suitable substituents for any heteroaryl group include 1 to 5, suitably 1 to 3, substituents selected from the list consisting of hydroxy, alkoxy, mono- and di-(alkyl)amino, halo, cyano, perhaloalkyl, amido, halo, alkyl, alkoxycarbonyl, mono- and di-(alkyl)aminocarbonyl, alkoxy, nitro, alkylsulphonyl, hydroxy, alkoxyalkyl, alkylthio, mono- and di-(alkyl)amino, and alkylcarbonylamino.

References to 'alkyl' refer to both straight chain and branched chain aliphatic isomers of the corresponding alkyl, suitably containing up to six carbon atoms.

References to 'cycloalkyl' refer to saturated alicyclic rings suitably containing 3-8 carbon atoms.

Suitable substituents for any cycloalkyl group include alkyl, halo, and hydroxy.

References to 'heterocyclyl' refer to monocyclic heterocyclic aliphatic rings containing 2 to 6, suitably 3 to 5, carbon atoms, and 1 to 3, heteroatoms selected from nitrogen, oxygen, and sulphur. Examples of heterocyclic rings include piperidinyl, uracilyl, and pyrandionyl.


Suitable substituents for any heterocyclyl group include alkylcarbonylamino, aminocarbonyl, cycloalkylaminocarbonyl,

alkylsulphonylamino, alkylcarbonyl, cycloalkylcarbonyl, mono- and di-(alkyl)aminocarbonyl, alkoxycarbonyl, alkylsulphonyl, alkoxyalkyl, and alkyl.

References to 'halogen' or 'halo' refer to iodo, bromo, chloro or fluoro, especially fluoro and chloro.

- 5 The compounds of formula (I) and salts and solvates thereof may be prepared by the methodology described hereinafter, constituting a further aspect of this invention.

Accordingly, there is provided a process for the preparation of a compound of formula (I) which process comprises the reaction of a compound of  
10 formula (II) with a compound of formula (III);



wherein;

- 15 R<sup>1</sup>, Y, R<sup>3</sup>, and R<sup>2</sup> are as hereinbefore defined for formula (I) in the presence of a base and an activating agent and optionally a peptide coupling agent, and thereafter, if required, carrying out one or more of the following optional steps:
- (i) converting a compound of formula (I) to a further compound of formula (I);
  - 20 (ii) removing any necessary protecting group;
  - (iii) preparing a salt or solvate of the compound so formed.

Suitably, the activating agent is 1-hydroxybenzotriazole (HOBT) or O-(7-azabenzotriazol-1-yl)-N,N,N<sup>1</sup>,N<sup>1</sup>-tetramethylammonium hexafluorophosphate.



- Examples of peptide coupling agents are 1,3-dicyclohexylcarbodiimide (DCC); 2-ethoxy-1-ethoxycarbonyl-1,2-dihydroquinoline (EEDQ) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide, or a salt thereof. Suitably, the peptide  
25 coupling agent is 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride.

- Typically, the compound of formula (III) in a suitable solvent such as a polar organic solvent, e.g. N,N-dimethylformamide, is treated with a suitable  
30 base, such as a tertiary amine, e.g. N,N-diisopropylethylamine and an activating agent e.g. O-(7-azabenzotriazol-1-yl)-N,N,N<sup>1</sup>,N<sup>1</sup>-tetramethylammonium hexafluorophosphate, followed by a compound of formula (II). Suitably the reaction is conducted at ambient temperature, e.g. 18-25°C, for a suitable time period e.g. 12 – 20 h.




A compound of formula (III) wherein  $R^3$  is hydrogen may be prepared either by Reaction (a) or Reaction (c). The S-enantiomer of a compound of formula (IV) may be prepared by Reaction (b).

Reaction (a). Reaction of the compound of formula (IV) with a compound of  
5 formula (V)



wherein  $R^2$  is as hereinbefore defined for formula (I) and A is a protected amino  
10 group, suitably phthalimido, followed by deprotection of the amino group to give a compound of formula (III) wherein  $R^3$  is hydrogen i.e. a compound of formula (IIIR)




15


wherein  $R^2$  is as hereinbefore defined, and optionally resolution of the resulting enantiomers of a compound of formula (IIIR);

or;

Reaction (b). Reaction of a compound of formula (IV) as hereinbefore defined  
20 with a compound of formula (VA)




wherein A is as hereinbefore defined for formula (V), followed by deprotection of  
25 the amino group to give the corresponding enantiomer of a compound of formula (III) wherein  $R^3$  is hydrogen i.e. a compound of formula (IIIE)



wherein  $R^2$  is as hereinbefore defined.

Reaction (c). Hydrolysis of a compound of formula (VI);



5

wherein T is trifluoroacetyl, and  $R^3$  and  $R^2$  are as hereinbefore defined, and optionally resolution of the resulting enantiomers of a compound of formula (III).



For both reactions (a) and (b), the cyclisation of the intermediate diols  
 10 (IIIBR) and (IIIBE) in the reaction between the compound of formula (IV) and a compound of formula (V) or (VA) is typically carried out under the Mitsunobu conditions as follows:

Typically, a mixture of the compound of formula (IV) and the compound of  
 formula (V) or formula (VA) in a suitable solvent, such as tetrahydrofuran, is  
 15 stirred, suitably for 20-24 hours at a suitable temperature, suitably the reflux temperature of the solvent, under an inert atmosphere, suitably an atmosphere of nitrogen. Further solvent is then added and the mixture cooled, suitably to 0-5°C. A suitable phosphine, suitably triphenyl phosphine, is added and the mixture stirred until all the solid is dissolved. A suitable azo compound, suitably  
 20 diisopropylazodicarboxylate, is then added over a period of time, suitably, 10-15 minutes, while maintaining the temperature at <7°C. The mixture is allowed to stand for a period of time, suitably 2-3 hours, then allowed to warm, suitably to 20-25°C. After a further period of standing, suitably 4-6 hours, further phosphine and azo compound are added. After a further period of standing, suitably 20-24  
 25 hours, the reaction mixture is concentrated to near dryness. A suitable alcohol, suitably propan-2-ol, is added and the concentration step repeated; the alcohol addition and concentration step is then repeated. Further alcohol is then added and the mixture heated to a temperature suitably between 65-75°C. After a suitable period, suitably 20-45 minutes, the resultant slurry is cooled, suitably to  
 30 20-25°C, and then allowed to stand, suitably for 1.5 – 3 hours, after which time the product is isolated by filtration. The filter bed is washed with more alcohol and then dried *in vacuo* at 35-45°C to yield the protected form of the compound of formula (IIIR) or formula (IIIE) respectively.

The removal of the protecting group from the product is typically carried  
 35 out as follows. A slurry of the protected form of the compound of formula (IIIR) or

formula (IIIE) in an appropriate polar solvent, suitably water, is heated to elevated temperature, suitably 70-75°C and then treated dropwise with a concentrated mineral acid, suitably concentrated sulphuric acid. The mixture is then heated at elevated temperature, suitably the reflux temperature of the solvent, for a suitable period of time, suitably 20-24 hours, after which the reaction mixture is cooled to 20-25°C and then treated with a suitable apolar solvent, suitably dichloromethane. A base, suitably 0.880 ammonia solution, is then added dropwise, maintaining the temperature to between 20-25°C. Further apolar solvent is then added, the aqueous phase then being separated and extracted with further apolar solvent. The combined organic phase is washed with water and then evaporated to dryness. The residue is reevaporated from the apolar solvent to give the compound of formula (IIIR) or formula (IIIE).

The process for the preparation of the protected form of the compound of formula (IIIR) or formula (IIIE) described above may also be undertaken in two stages, in which an intermediate compound of formula (IIIBR) or of formula (IIIBE) respectively;





wherein A is as hereinbefore defined for formulae (V) and (VA) and R<sup>2</sup> is as hereinbefore defined for formula (I);  
is isolated.

Typically, a mixture of the compound of formula (IV) and a compound of formula (V) or formula (VA) in a suitable solvent, such as tetrahydrofuran, is stirred, suitably for 20-24 hours at a suitable temperature, suitably the reflux temperature of the solvent, under an inert atmosphere, suitably an atmosphere of nitrogen. Further compound of formula (IV) is added and the mixture heated at a suitable temperature, suitably the reflux temperature of the solvent, under an inert atmosphere, suitably an atmosphere of nitrogen, for a suitable period of time, suitably 3-6 hours. The reaction mixture is then cooled, suitably to 20-25°C, and the compound precipitated by means of addition of a suitable co-solvent, suitably diisopropyl ether. The compound of formula (IIIBR) or formula (IIIBE) respectively is isolated by filtration, washed with further co-solvent and dried *in vacuo*.

A protected form of the compound of formula (IIIR) or formula (IIIE) may then be prepared from a compound of formula (IIIBR) or formula (IIIBE) under

similar conditions to that of the reaction between a compound of formula (IV) and formulae (V) or (VA) as hereinbefore described, but omitting the the reflux period prior to the addition of the phosphine and azo compounds.

- Reaction (c) is typically carried out by stirring a solution of the compound of formula (VI) in a suitable solvent, for example a mixture of methanol and water, and adding a suitable base, for example potassium carbonate. The mixture is stirred at a suitable temperature, for example those in the range 20-25°C for a suitable time, for example 16-20 hours followed by removal of the organic solvent in vacuo. Water is then added and the mixture extracted with a suitable organic solvent, for example ethyl acetate. The combined organic phases are washed with water and saturated aqueous sodium chloride solution before drying over a suitable drying agent, for example sodium sulphate, filtering and evaporation of the solvent in vacuo. The crude product is then purified by flash chromatography.
- The resolution of the compound of formula (IIIE) from the racemic product i.e. the compound of formula (IIIR) may be undertaken using techniques well known to those skilled in the art, for example preparative chiral high performance liquid chromatography (chiral HPLC) or by fractional crystallisation of diastereoisomeric salts.
- A compound of formula (VI) may be prepared by reaction of a compound of formula (VII) with a compound of formula (VIII)




wherein;

T, R<sup>3</sup> and R<sup>2</sup> are as hereinbefore defined and L<sup>2</sup> is a leaving group. A suitable leaving group, L<sup>2</sup> is a halo group such as chloro.

- The reaction between a compound of formula (VII) and a compound of formula (VIII) is typically carried out by stirring a solution of the compound of formula (VII) in a suitable solvent, for example N,N-dimethylformamide, under an inert atmosphere, for example an atmosphere of nitrogen, with the addition of a suitable base, for example potassium carbonate, and a suitable activating agent such as sodium iodide. A solution of a compound of formula (VIII) in a suitable solvent, such as N,N-dimethylformamide, is added dropwise to the mixture. The mixture is then stirred at a suitable temperature, for example a temperature in the range of 20-25°C, for a suitable period of time, for example 16-20 hours before removing the volatile components in vacuo. The residue is partitioned between a

suitable organic solvent, for example dichloromethane, and a saturated aqueous base, for example saturated aqueous sodium carbonate solution. The organic phase is then washed with additional saturated aqueous base and water before drying over a suitable drying agent, for example magnesium sulphate, filtering and evaporation of the solvent in vacuo to yield the crude product. The crude product is purified by flash chromatography.


A compound of formula (VII) may be prepared by reaction of a compound of formula (IX) with a compound of formula (X);




wherein R<sup>3</sup> and T are as hereinbefore defined and R<sub>x</sub> is an alkyl group, suitably ethyl.

The reaction between a compound of formula (IX) and a compound of formula (X) is typically carried out by stirring a solution of a compound of formula (IX) in a suitable organic solvent, for example methanol, under an inert atmosphere, for example an atmosphere of nitrogen, and then adding a solution of a compound of formula (X) in a suitable organic solvent, for example ether. The mixture is then stirred for a suitable period of time, for example 20-40 minutes at a suitable temperature, for example a temperature in the range of 20-25°C and the volatile components removed in vacuo. The residue is then dissolved in a suitable organic solvent, for example methanol, and the volatile components removed in vacuo.

Additionally, and in a further aspect, a compound of formula (I) wherein Y is -CH<sub>2</sub>- and R<sup>1</sup> is an unsubstituted or substituted N-linked heterocyclyl group i.e. a compound of formula (XI)



may be prepared by reaction of a compound of formula (XII) with a compound of formula (XIII);



5

wherein (XII) is an unsubstituted or substituted heterocyclyl group,  $L^2$  is a leaving group, and  $R^3$  and  $R^2$  are as hereinbefore defined for formula (I), and thereafter, if required, carrying out one or more of the following optional steps:

- (i) converting a compound of formula (I) to a further compound of formula (I);
- 10 (ii) removing any necessary protecting group;
- (iii) preparing a salt or solvate of the compound so formed.

Suitable leaving groups are halo groups, preferably bromo.

Typically, the reaction between a compound of formula (XII) and a compound of formula (XIII) will be conducted in a suitable organic solvent, such as for example dichloromethane, N,N-dimethylformamide or a mixture thereof, 15 suitably at ambient temperature, e.g. 18 - 25°C for an appropriate time period, e.g. 4 - 10h. A suitable base such as an alkali or alkaline earth metal carbonate, e.g. potassium carbonate, is then added.

A compound of formula (XIII) may be prepared by reaction of a 20 compound of formula (III) with a compound of formula (XIV)



wherein  $L^2$  is as hereinbefore defined for formula (XIII) and  $L^3$  is a leaving group 25 which is more labile than  $L^2$ , in the presence of a suitable base such as potassium carbonate. Examples of the leaving group,  $L^3$  include halo. Suitably,  $L^2$  and  $L^3$  are both bromo.

Typically, the reaction between a compound of formula (III) and a compound of formula (XIV) is conducted at low temperature, e.g. 0 - 5°C, in a 30 suitable organic solvent such as a haloalkane e.g. dichloromethane, for a suitable time period e.g. 20 - 60 mins.

The compounds of formulae (II), certain compounds of formula (III), certain compounds of formula (IV), (V), certain compounds of formula (VI), certain compounds of formula (VII), (VIII), (IX), (X), (XII), and (XIV) are known,

commercially available compounds, and/or may be prepared by analogy with known procedures, for examples those disclosed in standard reference texts of synthetic methodology such as *J. March, Advanced Organic Chemistry, 3rd Edition (1985), Wiley Interscience*.

- 5       The compounds of formulae (IIIBR), (IIIBE), and (XIII) are considered to be novel.

Accordingly, there is provided a compound of formula (IIIBR).

There is also provided a compound of formula (IIIBE).

There is also provided a compound of formula (XIII).

- 10       The above mentioned conversion of a compound of formula (I) into another compound of formula (I) includes any conversion which may be effected using conventional procedures, but in particular the said conversions include converting one group  $R^1$  into another group  $R^1$ .

- 15       The above mentioned conversion may be carried out using any appropriate method under conditions determined by the particular groups chosen. Thus, suitable conversions of one group  $R^1$  into another group  $R^1$  include:

- (a) converting a group  $R^1$  which represents a heterocyclyl group substituted with an alkoxy carbonyl group into a group  $R^1$  which represents an unsubstituted heterocyclyl group; such a conversion may be carried out using an appropriate conventional deprotection procedure, for example hydrolysing an appropriately protected compound of formula (I) with a suitable mineral acid;
- 20       (b) converting a group  $R^1$  which represents an unsubstituted heterocyclyl group into a group  $R^1$  which represents a heterocyclyl group substituted with an alkyl carbonyl group; such a conversion may be carried out using an appropriate conventional acylation procedure, for example treating an appropriately protected compound of formula (I) with a suitable acyl halide in the presence of a suitable base;
- 25       (c) converting a group  $R^1$  which represents an unsubstituted heterocyclyl group into a group  $R^1$  which represents a heterocyclyl group substituted with an alkylsulphonyl group; such a conversion may be carried out using an appropriate conventional sulphonylation procedure, for example treating an appropriately protected compound of formula (I) with a suitable alkylsulphonyl halide in the presence of a base;
- 30       (d) converting a group  $R^1$  which represents an unsubstituted heterocyclyl group into a group  $R^1$  which represents a heterocyclyl group substituted with an alkylaminocarbonyl group or a dialkylaminocarbonyl group; such a conversion may be carried out using an appropriate conventional urea-forming procedure, for example treating an appropriately protected compound of formula
- 40       (I) with a suitable isocyanate or carbamate, or carbamyl halide;

- (e) converting a group R<sup>1</sup> which represents an unsubstituted heterocyclyl group into a group R<sup>1</sup> which represents a heterocyclyl group substituted with an alkoxycarbonyl group; such a conversion may be carried out using an appropriate conventional carbamate-forming procedure, for example treating an appropriately protected compound of formula (I) with a suitable chloroformate ester;
- (f) converting a group R<sup>1</sup> which represents an unsubstituted heterocyclyl group into a group R<sup>1</sup> which represents a heterocyclyl group substituted with an aminocarbonyl group; such a conversion may be carried out using an appropriate conventional urea-forming procedure, for example treating an appropriately protected compound of formula (I) with 1,1'-carbonyldiimidazole followed by ammonia, and;
- (g) converting a group R<sup>1</sup> which represents an unsubstituted heterocyclyl group into a group R<sup>1</sup> which represents a heterocyclyl group substituted with an alkyl group; such a conversion may be carried out using an appropriate alkylation procedure, for example treating an appropriately protected compound of formula (I) with an alkyl halide in the presence of 2-tert-butylimino-2-diethylamino-1,3-dimethyl-perhydro-1,3,2-diazaphosphorine on polystyrene (BEMP resin).

The above mentioned conversions may as appropriate be carried out on any of the intermediate compounds mentioned herein.

The above mentioned conversions may as appropriate be carried out on any of the intermediate compounds mentioned herein.

Suitable protecting groups in any of the above mentioned reactions are those used conventionally in the art. The methods of formation and removal of such protecting groups are those conventional methods appropriate to the molecule being protected, for example those methods discussed in standard reference texts of synthetic methodology such as *P J Kocienski, Protecting Groups, (1994), Thieme*.

For any of the hereinbefore described reactions or processes, conventional methods of heating and cooling may be employed, for example electric heating mantles and ice/salt baths respectively. Conventional methods of purification, for example crystallisation and column chromatography may be used as required.

Where appropriate individual isomeric forms of the compounds of formula (I) may be prepared as individual isomers using conventional procedures such as the fractional crystallisation of diastereoisomeric derivatives or chiral high performance liquid chromatography (chiral HPLC).

The absolute stereochemistry of compounds may be determined using conventional methods, such as X-ray crystallography.



The salts and solvates of the compounds of formula (I) may be prepared and isolated according to conventional procedures.

Compounds of the invention may be tested for *in vitro* biological activity in accordance with the following assays:

5

(a) CCR-3 Binding Assay

A CCR-3 competition binding SPA (scintillation proximity assay) was used to assess the affinity of novel compounds for CCR-3. Membranes prepared from K562 cells stably expressing CCR-3 (2.5µg/well) were mixed with  
10 0.25mg/well wheat-germ agglutinin SPA beads (Amersham) and incubated in binding buffer (HEPES 50 mM, CaCl<sub>2</sub> 1 mM, MgCl<sub>2</sub> 5 mM, 0.5% BSA) at 4°C for 1.5 hr. Following incubation, 20 pM of [<sup>125</sup>I] eotaxin (Amersham) and increasing concentrations of compound (1pM to 30µM) were added and incubated in a 96 well plate for 2 hr at 22°C then counted on a Microbeta plate counter. The total  
15 assay volume was 100 µl. Competition binding data were analysed by fitting the data with a four parameter logistic equation. Data are presented as the mean pIC<sub>50</sub> values (negative logarithm of the concentration of compound which inhibits [<sup>125</sup>I]eotaxin binding by 50%) from at least two experiments.

20 (b) Eosinophil Chemotaxis Assay.

Compounds were evaluated for their inhibitory effect on eosinophil chemotaxis. Eosinophils were purified from human peripheral blood by standard CD16 cell depletion using a Miltenyi cell separation column and a magnetic Super Macs magnet as previously described (Motegi & Kita, 1998;  
25 J.Immunology. 161:4340-6). Cells were re-suspended in RPMI 1640/10% FCS solution and incubated with calcein-AM (Molecular Probes) at 37°C for 30 mins. Following incubation, the eosinophils were centrifuged at 400g for 5 min and re-suspended in RPMI/FCS at 2.2 million/ml. Cells were then incubated in the presence of increasing concentration of compounds (1 pM to 30 µM) at 37°C for  
30 30 mins. For control responses cells were incubated with RPMI/FCS only. The agonist eotaxin (an EC<sub>80</sub> concentration) was added to the lower chamber of a 96 well chemotaxis plate (5 µm filter: Receptor Technologies). Eosinophils (50 µl of 2 million/ml cells) were added to the top chamber of the filter plate and incubated at 37°C for 45 mins. Cells remaining on top of the chemotaxis filter were  
35 removed and the number of eosinophils which had migrated were quantified by reading the plate on a fluorescent plate reader. Inhibition curves for the effect of compounds on eosinophil chemotaxis were analysed by fitting the data with a four parameter logistic equation. Functional pK<sub>i</sub> values (fpK<sub>i</sub>) were generated using the equation below (Lazareno & Birdsall, 1995. Br.J.Pharmacol 109: 1110-  
40 9).

$$fpKi = \frac{IC_{50}}{1 + \frac{[Agonist]}{EC_{50}}}$$

The compounds of the Examples were tested in the CCR-3 binding  
 5 and/or eosinophil chemotaxis assays (assays (a) and (b)). The compounds of  
 the Examples tested in the CCR-3 binding assay possessed pIC<sub>50</sub> values in the  
 range 5.0 to 8.5. The compounds of the Examples tested in the CCR-3  
 eosinophil chemotaxis assay possessed fpKi values such as those given in the  
 table below:

Example No.	fpKi
1	8.2

10

Examples of disease states in which the compounds of the invention have  
 potentially beneficial anti-inflammatory effects include diseases of the respiratory  
 tract such as bronchitis (including chronic bronchitis), bronchiectasis, asthma  
 (including allergen-induced asthmatic reactions), chronic obstructive pulmonary  
 15 disease (COPD), cystic fibrosis, sinusitis and rhinitis.

Also included are diseases of the gastrointestinal tract such as intestinal  
 inflammatory diseases including inflammatory bowel disease (e.g. Crohn's  
 disease or ulcerative colitis) and intestinal inflammatory diseases secondary to  
 radiation exposure or allergen exposure.

20

Furthermore, compounds of the invention may be used to treat nephritis;  
 skin diseases such as psoriasis, eczema, allergic dermatitis and hypersensitivity  
 reactions; and diseases of the central nervous system which have an  
 inflammatory component (eg. Alzheimer's disease, meningitis, multiple  
 sclerosis), HIV and AIDS dementia.

25

Compounds of the present invention may also be of use in the treatment  
 of nasal polyposis, conjunctivitis or pruritis.

Further examples of disease states in which compounds of the invention  
 have potentially beneficial effects include cardiovascular conditions such as  
 atherosclerosis, peripheral vascular disease and idiopathic hypereosinophilic

30

syndrome.

Compounds of the invention may be useful as immunosuppressive  
 agents and so have use in the treatment of auto-immune diseases such as  
 allograft tissue rejection after transplantation, rheumatoid arthritis and diabetes.

Compounds of the invention may also be useful in inhibiting metastasis.

35

Diseases of principal interest include asthma, COPD and inflammatory  
 diseases of the upper respiratory tract involving seasonal and perennial rhinitis.

It will be appreciated by those skilled in the art that references herein to treatment or therapy extend to prophylaxis as well as the treatment of established conditions.

As mentioned above, compounds of formula (I) are useful as therapeutic agents.

There is thus provided as a further aspect of the invention a compound of formula (I) or a physiologically acceptable salt or solvate thereof for use as an active therapeutic agent.

There is also therefore provided a compound of formula (I), or a physiologically acceptable salt or solvate thereof, for use in the treatment of inflammatory conditions, e.g. asthma or rhinitis.

According to another aspect of the invention, there is provided the use of a compound of formula (I) or a physiologically acceptable salt or solvate thereof for the manufacture of a medicament for the treatment of inflammatory conditions, eg. asthma or rhinitis.

In a further or alternative aspect there is provided a method for the treatment of a human or animal subject suffering from or susceptible to an inflammatory condition e.g. asthma or rhinitis, which method comprises administering an effective amount of a compound of formula (I) or a physiologically acceptable salt or solvate thereof.

The compounds according to the invention may be formulated for administration in any convenient way.

There is thus further provided a pharmaceutical composition comprising a compound of formula (I), or a physiologically acceptable salt or solvate thereof, and optionally one or more physiologically acceptable diluents or carriers.

There is also provided a process for preparing such a pharmaceutical formulation which comprises admixing the compound of formula (I) or a physiologically acceptable salt or solvate thereof with one or more physiologically acceptable diluents or carriers.

The compounds according to the invention may, for example, be formulated for oral, inhaled, intranasal, buccal, parenteral or rectal administration, preferably for oral administration.

Tablets and capsules for oral administration may contain conventional excipients such as binding agents, for example syrup, acacia, gelatin, sorbitol, tragacanth, mucilage of starch, cellulose or polyvinyl pyrrolidone; fillers, for example, lactose, microcrystalline cellulose, sugar, maize- starch, calcium phosphate or sorbitol; lubricants, for example, magnesium stearate, stearic acid, talc, polyethylene glycol or silica; disintegrants, for example, potato starch, croscarmellose sodium or sodium starch glycollate; or wetting agents such as

sodium lauryl sulphate. The tablets may be coated according to methods well known in the art.

Oral liquid preparations may be in the form of, for example, aqueous or oily suspensions, solutions, emulsions, syrups or elixirs, or may be presented as a dry product for constitution with water or other suitable vehicle before use. Such liquid preparations may contain conventional additives such as suspending agents, for example, sorbitol syrup, methyl cellulose, glucose/sugar syrup, gelatin, hydroxymethyl cellulose, carboxymethyl cellulose, aluminium stearate gel or hydrogenated edible fats; emulsifying agents, for example, lecithin, sorbitan mono-oleate or acacia; non-aqueous vehicles (which may include edible oils), for example almond oil, fractionated coconut oil, oily esters, propylene glycol or ethyl alcohol; or preservatives, for example, methyl or propyl *p*-hydroxybenzoates or sorbic acid. The preparations may also contain buffer salts, flavouring, colouring and/or sweetening agents (e.g. mannitol) as appropriate.

For buccal administration the compositions may take the form of tablets or lozenges formulated in conventional manner.

The compounds may also be formulated as suppositories, e.g. containing conventional suppository bases such as cocoa butter or other glycerides.

The compounds according to the invention may also be formulated for parenteral administration by bolus injection or continuous infusion and may be presented in unit dose form, for instance as ampoules, vials, small volume infusions or pre-filled syringes, or in multidose containers with an added preservative. The compositions may take such forms as solutions, suspensions, or emulsions in aqueous or non-aqueous vehicles, and may contain formulatory agents such as anti-oxidants, buffers, antimicrobial agents and/or tonicity adjusting agents. Alternatively, the active ingredient may be in powder form for constitution with a suitable vehicle, e.g. sterile, pyrogen-free water, before use. The dry solid presentation may be prepared by filling a sterile powder aseptically into individual sterile containers or by filling a sterile solution aseptically into each container and freeze-drying.

The compounds and pharmaceutical compositions according to the invention may also be used in combination with other therapeutic agents, for example antihistaminic agents, anticholinergic agents, anti-inflammatory agents such as corticosteroids, e.g. fluticasone propionate, beclomethasone dipropionate, mometasone furoate, triamcinolone acetonide or budesonide; or non-steroidal anti-inflammatory drugs (NSAIDs) e.g. sodium cromoglycate, nedocromil sodium, PDE-4 inhibitors, leukotriene antagonists, iNOS inhibitors, tryptase and elastase inhibitors, beta-2 integrin antagonists and adenosine 2a agonists; or beta adrenergic agents such as salmeterol, salbutamol, formoterol, fenoterol or terbutaline and salts thereof; or antiinfective agents e.g. antibiotic

agents and antiviral agents. It will be appreciated that when the compounds of the present invention are administered in combination with other therapeutic agents normally administered by the inhaled or intranasal route, that the resultant pharmaceutical composition may be administered by the inhaled or intranasal

5 route.

Compounds of the invention may conveniently be administered in amounts of, for example, 0.001 to 500mg/kg body weight, preferably 0.01 to 500mg/kg body weight, more preferably 0.01 to 100mg/kg body weight, and at any appropriate frequency e.g. 1 to 4 times daily. The precise dosing regimen  
10 will of course depend on factors such as the therapeutic indication, the age and condition of the patient, and the particular route of administration chosen.

Throughout the description and the claims which follow, unless the context requires otherwise, the word 'comprise', and variations such as 'comprises' and 'comprising', will be understood to imply the inclusion of a stated  
15 integer or step or group of integers but not to the exclusion of any other integer or step or group of integers or steps.

The invention is illustrated by reference to, but is in no way limited by, the following Examples.

For the avoidance of doubt, the free bond on the R<sup>1</sup> groups as presented  
20 in the Tables signifies the point of attachment of the R<sup>1</sup> groups to the residue of the molecule.

It should be noted that, for clarity, compounds of the Descriptions and the Examples are referred to by number, for example "Description 3" and "Example 5". The structures of the compounds so referred to are given in Table 1 for the  
25 Examples and Table 2 for the Descriptions.

#### General experimental details

##### Mass Directed Automated Preparative HPLC column, conditions and eluent

30 Mass directed automated preparative high performance liquid chromatography was carried out using an LCABZ+ 5 $\mu$ m (5cm x 10mm internal diameter) column, employing gradient elution using two solvent systems, (A) 0.1% formic acid in water, and (B) 95% acetonitrile and 0.5% formic acid in water, at a flow rate of 8ml min<sup>-1</sup>. Mass spectrometry was carried out using a VG Platform Mass  
35 Spectrometer, with an HP1100 Diode Array Detector and Accurate Flow Splitter.

##### LC/MS System

This system used an 3 $\mu$ m ABZ+PLUS (3.3cm x 4.6mm internal diameter) column, eluting with solvents: A – 0.1%v/v formic acid + 0.077% w/v ammonium  
40 acetate in water; and B – 95:5 acetonitrile:water + 0.05%v/v formic acid, at a flow

rate of 3 ml per minute. The following gradient protocol was used: 100% A for 0.7mins; A+B mixtures, gradient profile 0 – 100% B over 3.5mins; hold at 100%B for 1.1mins; return to 100% A over 0.2mins.

The LC/MS system used a micromass spectrometer, with electrospray ionisation  
5 mode, positive and negative ion switching, mass range 80-1000 a.m.u.

#### Thermospray Mass Spectra

Thermospray Mass Spectra were determined on a HP 5989A engine mass spectrometer, +ve thermospray, source temperature 250°C, probe temperatures  
10 120°C (stem), 190°C (tip), detection mass range 100-850 a.m.u. Compounds were injected in 10µl of a mixture of solvents comprising 65% methanol and 35% 0.05M aqueous ammonium acetate, at a flow rate of 0.7ml/min.

#### Solid phase extraction (ion exchange)

15 'SCX' refers to Isolute Flash SCX-2 sulphonic acid solid phase extraction cartridges.

All temperatures are in °C

#### 20 Descriptions

##### Description 1: 2,2,2-Trifluoro-N-(morpholin-2-ylmethyl)acetamide

To a stirred solution of morpholin-2-ylmethylamine (3.1g) in methanol (70ml) under nitrogen was added an ethereal solution of ethyl- $\alpha,\alpha,\alpha$ -trifluoroacetate (5ml in 20ml ether) which had been washed with saturated aqueous sodium  
25 bicarbonate, water and brine, and dried. The mixture was stirred for 30 min at 22°C before removal of all volatiles in vacuo. The residue was dissolved in methanol (10ml) and the volatiles again removed in vacuo to give the title compound as a white crunchy foam (4.9g).  
Thermospray Mass Spectrum  $m/z$  213 [MH<sup>+</sup>].

30

##### Description 2: N-[[4-(3,4-Dichlorobenzyl)morpholin-2-yl]methyl]-2,2,2-trifluoroacetamide

To a stirred solution of Description 1 (3.3g) in N,N-dimethylformamide (50ml) under nitrogen was added potassium carbonate (2.46g) and sodium iodide  
35 (2.12g). A solution of 3,4-dichlorobenzyl chloride (2ml) in N,N-dimethylformamide (10ml) was added dropwise to the mixture. The mixture was stirred at 22°C for 18h before the volatiles were removed in vacuo. The residue was partitioned between dichloromethane (100ml) and saturated aqueous sodium carbonate solution (50ml). The organic phase was subsequently washed  
40 with additional saturated aqueous sodium carbonate solution (2 x 50ml) and

water (50ml) before drying over magnesium sulphate, filtering and evaporation of the solvent in vacuo to give a pale yellow oil. The oil was purified by Biotage flash chromatography on a 90g silica cartridge eluting with 25% ethyl acetate in cyclohexane, to give the title compound as a colourless oil (2.97g).

5 LC/MS ( $R_t$  2.63 min, Mass Spectrum  $m/z$  371 [ $MH^+$ ]).

Description 3: [4-(3,4-Dichlorobenzyl)morpholin-2-yl]methylamine

To a stirred solution of Description 2 (2.97g) in methanol (15ml) and water (5ml) was added potassium carbonate (5.53g). The mixture was stirred at 22°C for  
10 18h before the methanol was removed in vacuo. Water (25ml) was added and the mixture extracted with ethyl acetate (3 x 30ml). The combined organic phases were washed with water (5ml) and saturated aqueous sodium chloride solution (10ml) before drying over sodium sulphate, filtering and evaporation of the solvent in vacuo to give a pale yellow oil. The oil was purified by Biotage  
15 flash chromatography on a 90g silica cartridge eluting with 75:8:1 dichloromethane/ethanol/0.880 ammonia solution. The required fractions were combined and the solvent evaporated in vacuo to give the title compound as a colourless oil (1.85g).

LC/MS  $R_t$  1.77 min, Mass Spectrum  $m/z$  275 [ $MH^+$ ].

20

Description 4: [4-(3,4-Dichlorobenzyl)morpholin-2-yl]methylamine (alternative synthesis)

A mixture of 2-[(3,4-dichlorobenzyl)amino]ethanol (Chem Abs No. 40172-06-3, 0.980g) and 2-(oxiran-2-ylmethyl)-1H-isoindole-1,3(2H)-dione (1.10g) was  
25 heated at 80°C under nitrogen for 3h. The resulting solid mass was treated with concentrated sulphuric acid (1.5ml) then stirred at 150°C for 24h. The mixture was treated with water (100ml) then washed with ethyl acetate (2x100ml). The dark aqueous phase was basified to ~pH 12 using 5M aqueous sodium hydroxide, then extracted with ethyl acetate (2x100ml). The combined organic  
30 extracts were washed with water and brine, dried ( $Na_2SO_4$ ) and concentrated under vacuum to give the title compound as a brown oil (1.02g).  
Mass spec.  $m/z$  275 ( $MH^+$ ).

Description 5: 1-[(2S)-4-(3,4-Dichlorobenzyl)morpholin-2-yl]methylamine

35 Description 3 (racemic mixture, 8g) was separated into its single enantiomers by preparative chiral-HPLC. The separation was carried out using a 2" x 22cm Chiralpak AD 20 $\mu$ m column, Merck self pack DAC system, eluting with 95:5:0.1 (v/v) heptane : absolute ethanol: diethylamine (flow rate: 55ml/min over 40min, UV detection 225nm); sample load preparation: 400mg sample in 20ml 3:2 (v/v)  
40 absolute ethanol: system eluent.

The title compound (2.49g) was obtained as follows: preparative HPLC retention time 23.0 min.

Description 5 (Alternative procedure)

- 5 A slurry of Description 7 (1.00g) in water (8.5ml) was heated to 75° and then treated dropwise with concentrated sulphuric acid (2.5ml). The mixture was then heated at reflux. After 23h the reaction mixture was cooled to 22° and then treated with dichloromethane (6ml). 880 Ammonia solution (7ml) was then added dropwise with cooling. More dichloromethane (10ml) was added. The
- 10 aqueous phase was separated and extracted with more dichloromethane (10ml). The combined organic phase was washed with water (5ml) and then evaporated to dryness. The residue was redissolved in dichloromethane and the solvent re-evaporated to give the product as an oil (662mg).

- 15 Description 6: 1-[(2S)-4-(3,4-Dichlorobenzyl)morpholin-2-yl]methanamine salt with D-tartaric acid 1:1

- Description 3 (0.613g) was dissolved in methanol (12.3ml). D-Tartaric acid (0.335g) was added and the slurry was heated to reflux for 50min. The mixture was allowed to cool to 0-5°C and the precipitate isolated by filtration to give the
- 20 title compound as a white solid (0.4g).

ee: 76%ee

Chiral analytical HPLC (Chiralpak AD column, 4.6 x 250mm, eluent 50:50:0.1 MeOH: EtOH: Butylamine, flow rate 0.5ml/min, UV detection at 220nm), Rt 8.9min.

25


Description 7: 2-[4-(3,4-Dichloro-benzyl)-morpholin-2-ylmethyl]-isoindole-1,3-dione



- A mixture of 2-[(3,4-dichlorobenzyl)amino]ethanol (2.038 g) and (S)-2-(oxiran-2-ylmethyl)-1H-isoindole-1,3(2H)-dione (2.032g) in tetrahydrofuran (3.3ml) was stirred and heated at reflux under nitrogen. After 21.5h more tetrahydrofuran (12.5ml) was added and the mixture was cooled to 3°. Triphenyl phosphine (2.793g) was added and the mixture was stirred until all the solid had dissolved. Diisopropylazodicarboxylate (2.1ml) was then added over 12min maintaining the temperature at <7°. After 2.25h the mixture was allowed to warm to 22°. After 5.3h more triphenylphosphine (121mg) and diisopropylazodicarboxylate (0.09ml) were added. After 22.5h the reaction mixture was concentrated to near dryness.
- 10 Propan-2-ol (12ml) was added and the concentration repeated, this was repeated once more. More propan-2-ol (12ml) was added and the mixture was heated to 70°. After 0.5h the slurry was cooled to 22° and then after a further 2h the product was collected. The bed was washed with propan-2-ol (2x4ml) and then dried in vacuo at 40° to give the product, (2.622g).


15

Description 8: 3-(4-Ethyl-2,3-dioxo-piperazin-1-yl)propionic acid tert-butyl ester




- 20 A suspension of 2-tert-butylimino-2-diethylamino-1,3-dimethyl-perhydro-1,3,2-diazaphosphorine on polystyrene (BEMP resin, loading 2.3mmol/g, 0.54g) in acetonitrile (3ml) was treated with 1-ethyl-piperazine-2,3-dione (0.071g) and tert-butyl-3-bromopropionate (0.125g), and the mixture shaken at 22° for 16h. The resin was filtered off and washed with acetonitrile, and the filtrate and washings
- 25 combined and evaporated in vacuo to give a white solid. The solid was applied in chloroform to a silica gel cartridge (Varian Bond Elut, 2g), and eluted sequentially with chloroform, ether, ethyl acetate and acetone. The acetone fraction was evaporated to give Description 8 as a white solid (0.104g).

- 30 Description 9: 3-(4-Ethyl-2,3-dioxo-piperazin-1-yl)propionic acid



Description 8 (0.104g) was dissolved in 1,4-dioxane (3ml) and treated with 4M hydrogen chloride in 1,4-dioxane (3ml). The mixture was stirred at 22° for 18h,  
 5 and evaporated in vacuo to give Description 9 as a colourless gum (0.078g).  
 Thermospray Mass Spectrum m/z 232 [MNH<sub>4</sub><sup>+</sup>]

Description 10: (5-Hydroxy-4-oxo-4H-pyran-2-yl)acetic acid




10

A solution of (5-benzyloxy-4-oxo-4H-pyran-2-yl)acetonitrile (3.0g) (for preparation details see Journal of Medicinal Chemistry (1979), 22(1), p99-106) in conc. hydrochloric acid (15ml) was stirred at 20°C for 72h. The mixture was poured  
 15 onto ice (approx. 45g) and extracted with ether (4x25ml). The aqueous phase was concentrated *in vacuo* and the residue triturated with 1,4-dioxane (20ml). The solid was removed by filtration and the mother liqueur concentrated *in vacuo* to give a solid, which was re-crystallised from ethyl acetate (10ml)/1,4-dioxane (10ml) to give the title compound as buff coloured microcrystals (0.74g).  
 20 Mpt. 132-135°C  
 TLC (Silica plate, 100% ethyl acetate) R<sub>f</sub> = 0.30 (streaks to baseline), visualised by U.V., KMnO<sub>4</sub> spray

#### Examples

25 Synthetic Method A

#### Example 26




A solution of 4-(2-carboxy-ethyl)-piperidine-1-carboxylic acid tert-butyl ester (J. Med. Chem. (1998), 41(14), 2492-2502) (0.462g) in N,N-dimethylformamide  
 5 (4ml) was treated with N,N-diisopropylethylamine (0.627ml) and O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethylammonium hexafluorophosphate (0.684g) followed by Description 5 (0.495g), and the mixture stirred at room temperature for 16 hours.

The solution was concentrated to remove most of the solvent, dichloromethane  
 10 (25ml) was added and this solution washed successively with saturated aqueous sodium hydrogen carbonate (2 x 25ml), dilute aqueous sodium chloride (25ml) and saturated aqueous sodium chloride (25ml). The solution was concentrated in vacuo and purified by chromatography using a Biotage silica gel cartridge, eluting with 80 – 100% ethyl acetate/cyclohexane followed by 1% methanol/ethyl  
 15 acetate. Appropriate fractions were combined and evaporated to give the title compound (0.485g) as a clear oil. LC-MS: Rt 2.89 min, Mass Spectrum m/z 514 [MH<sup>+</sup>]

#### Example 13 (HCl salt)

20



A solution of Example 26 (0.380g) in 1,4-dioxane (2ml) was treated with hydrogen chloride in 1,4-dioxane (4M, 4ml) and the resulting solution was stirred  
 25 under nitrogen for two hours at room temperature, followed by concentration in vacuo to give a pale yellow solid. This was azeotroped with dichloromethane

(10ml), triturated with ether (10ml) and concentrated in vacuo to give the title compound (0.342g) as a pale yellow solid.

LC-MS: Rt 1.91 min, Mass Spectrum m/z 414 [MH<sup>+</sup>]


5 Example 13 (Free base)

A solution of Example 26 (0.167g) in 1,4-dioxane (1ml) was treated with hydrogen chloride in 1,4-dioxane (4M, 3ml) and the resulting solution was stirred under nitrogen for eighteen hours at room temperature then left to stand for two days. The mixture was concentrated in vacuo and the residue azeotroped with

10 methanol followed by dichloromethane. The product was dissolved in methanol and loaded onto an SCX (5g) ion exchange cartridge, which had been pre-treated with methanol and which was then eluted with methanol and 10% 0.880 ammonia/methanol. The basic fractions were combined and concentrated in vacuo to give the title compound (0.127g).

15 LC-MS: Rt 1.85 min, Mass Spectrum m/z 414 [MH<sup>+</sup>]

Example 12




20 A solution of Example 13 (HCl salt, 0.055g) in dichloromethane (2ml) was treated with N,N-diisopropylethylamine (0.06ml) followed by acetyl chloride (0.010ml) and the resulting solution was stirred at room temperature for three hours. The solvent was then evaporated under a stream of nitrogen to dryness, and the residue dissolved in methanol and loaded onto an SCX (1g) ion exchange

25 cartridge, which had been pre-treated with methanol and which was then eluted with methanol and 10% 0.880 ammonia/methanol. The basic fractions were combined and concentrated to give a residue which was further purified by chromatography on silica gel (Varian Bond Elute Cartridge, 1g), eluting with 0.5% methanol/ethyl acetate. Appropriate fractions were combined and concentrated

30 in vacuo to give the title compound (0.014g) as a clear gum.


LC-MS: Rt 2.29 min, Mass Spectrum m/z 456 [MH<sup>+</sup>]

Synthetic Method B

Example 10

- 5 A solution of Example 13 (HCl salt, 0.055g) in dichloromethane (2ml) was treated with N,N-diisopropylethylamine (0.06ml) followed by methane sulphonyl chloride (0.010ml) and the resulting solution was stirred at room temperature for three hours. The solvent was then evaporated under a stream of nitrogen to dryness, and the residue dissolved in methanol and loaded onto an SCX (2g) ion
- 10 exchange cartridge, which had been pre-treated with methanol and which was then eluted with methanol and 10% 0.880 ammonia/methanol. Basic fractions were combined and concentrated to give a residue which was further purified by chromatography on silica gel (Varian Bond Elut Cartridge, 1g), eluting with 90-100% ethyl acetate/cyclohexane followed by 1-2% methanol/ethyl acetate.
- 15 Appropriate fractions were combined and concentrated in vacuo to give the title compound (0.026g).


LC-MS: Rt 2.42 min, Mass Spectrum m/z 492 [MH<sup>+</sup>]

Synthetic Method C20 Example 11

- A solution of Example 26 (0.015g) in 1,4-dioxane (0.5ml) was treated with
- 25 hydrogen chloride in 1,4-dioxane (4M, 1ml) and the solution stirred at room temperature for sixteen hours; the solvent was then evaporated under a stream

of nitrogen to dryness. The resulting yellow solid was treated with dichloromethane (1.5ml) and N,N-diisopropylethylamine (1.2ml) followed by diethylcarbonyl chloride (0.010ml). After stirring at room temperature under nitrogen for three hours, the solution was concentrated in vacuo and the residue dissolved in methanol. The solution was loaded onto an SCX (1g) ion exchange cartridge, which had been pre-treated with methanol and which was then eluted with methanol and 10% 0.880 ammonia/methanol. Basic fractions were combined and concentrated to give the title compound (0.010g) as a clear oil. LC/MS Rt 2.65min, Mass Spectrum m/z 513 [MH<sup>+</sup>]

10


Synthetic Method DExample 14

15

A solution of Example 13 (free base, 0.127g) in N,N-dimethylformamide (2ml) was added dropwise to a solution of 1,1-carbonyldiimidazole in N,N-dimethylformamide (2ml) and the resulting mixture stirred at room temperature under nitrogen for five hours. The solution was then concentrated in vacuo to ca. 2ml and 0.880 ammonia solution (4ml) was added. After stirring at room temperature under nitrogen for sixteen hours, the mixture was concentrated in vacuo, redissolved in N,N-dimethylformamide (0.75ml) and 0.880 ammonia solution (4ml) was added. The mixture was heated at 50° in a thick walled sealed vial (Reacti-vial<sup>TM</sup>) for three hours then allowed to cool. The solution was concentrated in vacuo and the residue dissolved in methanol. The solution was loaded onto an SCX (2g) ion exchange cartridge, which had been pre-treated with methanol and which was then eluted with methanol and 10% 0.880 ammonia/methanol. The basic fractions were combined and concentrated to give a residue which was further purified by chromatography on silica gel (Biotage cartridge), eluting with 95:5.5:0.5 then 92:8:1 dichloromethane/ethanol/0.880 ammonia. Appropriate fractions were combined and evaporated to give a residue which was dissolved in ethyl acetate (25ml)

and washed with water (5 x 25ml). The organic phase was dried ( $\text{MgSO}_4$ ), filtered and evaporated to give the title compound (0.018g) as a clear gum. LC/MS Rt 2.15min, Mass Spectrum  $m/z$  457 [ $\text{MH}^+$ ]

## 5 Synthetic Method E




### Example 2

- 10 A solution of Example 13 (free base) (0.037g) in dichloromethane (2ml) and N,N-dimethylformamide (0.2ml) was treated with ethyl isocyanate (0.008ml) and the mixture was stirred at room temperature under nitrogen for 16h. The mixture was applied directly to an Isolute SCX ion exchange cartridge (2g) and eluted with methanol followed by 10% 0.880 ammonia in methanol. Evaporation of the
- 15 methanol/ammonia fraction gave a gum (0.022g), which was purified by mass directed preparative HPLC to give the title compound as a colourless gum (0.0088g). LC/MS Rt 2.28min, Mass Spectrum  $m/z$  485 [ $\text{MH}^+$ ]

## 20 Synthetic Method F

### Example 9



- 25 A solution of 4-nitrophenyl N-methylcarbamate (0.0195g) in dichloromethane (1ml) was added to a stirred solution of Example 13 (free base) (0.037g) and


N,N-diisopropylethylamine (0.035ml) in dichloromethane (2ml) and N,N-dimethylformamide (0.07ml), and the mixture was stirred at room temperature for 16h. The mixture was applied directly to an Isolute SCX ion exchange cartridge (2g) and eluted with methanol followed by 10% 0.880 ammonia in methanol.

- 5 Evaporation of the methanol/ammonia fraction gave a gum (0.025g), which was purified by mass directed preparative HPLC to give the title compound as a colourless gum (0.0186g).

LC/MS Rt 2.26min, Mass Spectrum m/z 471 [MH<sup>+</sup>]

#### 10 Synthetic Method G

##### Example 6



Methyl chloroformate (0.0077ml) was added to a stirred solution of Example 13


- 15 (free base) (0.037g) and N,N-diisopropylethylamine (0.035ml) in dichloromethane (2ml) and N,N-dimethylformamide (0.07ml), and the mixture was stirred at room temperature for 16h. The mixture was applied directly to an Isolute SCX ion exchange cartridge (2g) and eluted with methanol followed by 10% 0.880 ammonia in methanol. Evaporation of the methanol/ammonia fraction
- 20 gave a gum (0.020g), which was purified by mass directed preparative HPLC to give the title compound as a colourless gum (0.0129g).

LC/MS Rt 2.50min, Mass Spectrum m/z 472 [MH<sup>+</sup>]

#### Synthetic Method H


##### 25 Example 18





To a stirred solution of Description 5 (0.0315g) in dichloromethane (2ml) cooled in an ice bath was added bromoacetyl bromide (0.01ml). The mixture was stirred  
5 for 30min and then allowed to warm to 20°. A solution of N-piperidin-4-yl-acetamide hydrochloride (U.S. 5,563,141) (0.0225g) in N,N-dimethylformamide (2ml) was added to the mixture before stirring for a further 5h. Potassium carbonate (0.0158mg) was added, and stirring continued at 20° for a further 16.5h. During a further 74.5h, further portions of potassium carbonate  
10 (0.0158mg and 0.0475g) were added with continued stirring at 20°. After stirring for a further 48h, the mixture was diluted with methanol (ca. 2ml) and applied to a 5g SCX ion-exchange cartridge, pre-conditioned with methanol. The cartridge was eluted with methanol and 10% 0.880 ammonia solution in methanol. The first ammonia fraction was evaporated in vacuo and the residue was further  
15 purified by Biotage™ flash chromatography (silica gel), eluting with 150:8:1 dichloromethane/ethanol/0.880 ammonia solution. The required fractions were combined and the solvent evaporated in vacuo to give a residue, which was further purified by dissolving in dichloromethane (2ml) and applying to a 1g silica gel cartridge (Varian Bond Elut) pre-conditioned with dichloromethane. The  
20 cartridge was successively eluted with dichloromethane, chloroform, diethylether, ethyl acetate, acetonitrile, acetone and methanol. The acetone fractions was evaporated in vacuo to give the title compound (0.0083g) as a colourless glass.  
LC/MS:  $R_t = 1.84\text{min}$ ,  $m/z$  457,459  $[\text{MH}^+]$

25 Synthetic Method I  
Example 19




A solution of Example 24 (0.039g) in acetonitrile (2ml) and N,N-dimethylformamide (0.5ml) was added to 2-tert-butylimino-2-diethylamino-1,3-dimethyl-perhydro-1,3,2-diazaphosphorine on polystyrene (BEMP resin, 0.104g) and the mixture was shaken at room temperature for 0.5h. A solution of iodomethane (0.007ml) in acetonitrile (0.1ml) was added, and the mixture was shaken at 22° for 16h. The resin was filtered off and washed with acetonitrile (3x2ml) and methanol (3x2ml). The filtrate and washings were applied to an Isolute SCX ion exchange cartridge (1g) and eluted with methanol followed by 10% 880 ammonia in methanol. Evaporation of the methanol/ammonia fraction gave a gum (0.034g), which was purified by mass directed preparative HPLC to give the title compound as a colourless gum (0.0234g).  
LC/MS Rt 2.17min, Mass Spectrum m/z 429 [MH<sup>+</sup>]

15

Method H

Example 27: N-[4-(3,4-Dichlorobenzyl)morpholin-2-ylmethyl]-2-(5-hydroxy-4-oxo-4H-pyran-2-yl)acetamide trifluoroacetate



20


To Description 10 (0.034g) in acetonitrile (1ml) was added a portion (0.25ml) of a solution of Description 9 (0.281g) in acetonitrile (1.1ml). To this mixture was added 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.058g), 1-hydroxybenzotriazole (0.035g) and N,N-diisopropylethylamine (0.035ml). Further acetonitrile (2ml) was added and the mixture stirred at 20°C for 4 days. The

mixture was purified by mass-directed-autoprep and the required fractions were combined, had trifluoroacetic acid added, and the volatiles evaporated to give the title compound (0.031g).









LCMS R<sub>t</sub> 2.19 min, *m/z* 427 [MH<sup>+</sup>]









5







Table 1



Ex. No.	Synthetic Method	R <sup>1</sup>	R <sup>2</sup>	Stereochem at position (*)	Calculated Mol. Wt.	Observed Mol. Wt. (LC/MS) [M+H] <sup>+</sup> of lowest mass isomer unless otherwise indicated
1	A		3,4-di-ClPh	S	482.455	482
2*	E		3,4-di-ClPh	S	485.45	485
3*	E		3,4-di-ClPh	S	499.48	499
4	A		3,4-di-ClPh	S	484.471	484
5	G		3,4-di-ClPh	S	486.443	486
6	G		3,4-di-ClPh	S	472.416	472

Ex. No.	Synthetic Method	R <sup>1</sup>	R <sup>2</sup>	Stereochem at position (*)	Calculated Mol. Wt.	Observed Mol. Wt. (LC/MS) [M+H] <sup>+</sup> of lowest mass isomer unless otherwise indicated
7	A		3,4-di-ClPh	S	470.444	470
8	B		3,4-di-ClPh	S	506.496	506
9*	F		3,4-di-ClPh	S	471.43	471
10	B		3,4-di-ClPh	S	492.469	492
11	C		3,4-di-ClPh	S	513.513	513
12	A		3,4-di-ClPh	S	457.404	456
13+	A		3,4-di-ClPh	S	414.37	414
14	D		3,4-di-ClPh	S	457.404	457

Ex. No.	Synthetic Method	R <sup>1</sup>	R <sup>2</sup>	Stereochem at position (*)	Calculated Mol. Wt.	Observed Mol. Wt. (LC/MS) [M+H] <sup>+</sup> of lowest mass isomer unless otherwise indicated
15*	F		3,4-di-ClPh	S	497.46	497
16	A		3,4-di-ClPh	S	500.47	500
17	H		3,4-di-ClPh	S	493.456	493
18	H		3,4-di-ClPh	S	457.404	457
19	I		3,4-di-ClPh	S	429.30	429
20	A		3,4-di-ClPh	S	429.306	429
21	A		3,4-di-ClPh	S	429.306	429
22	A		3,4-di-ClPh	S	443.333	443

Ex. No.	Synthetic Method	R <sup>1</sup>	R <sup>2</sup>	Stereochem at position (*)	Calculated Mol. Wt.	Observed Mol. Wt. (LC/MS) [M+H] <sup>+</sup> of lowest mass isomer unless otherwise indicated
23	I		3,4-di-ClPh	S	443.33	443
24	A		3,4-di-ClPh	S	415.27	415
25	A		3,4-di-ClPh	S	471.388	471
26	A		3,4-di-ClPh	S	514.49	514
27 <sup>^</sup>	H		3,4-di-ClPh	RS	427.29	427
28	H		3,4-di-ClPh	RS	441.32	441




\* Examples 2, 3, 9, and 15 are formate salts

+ Example 13 is the hydrochloride salt

<sup>^</sup> Example 27 is the trifluoroacetate salt

5

Table 2

Description No.	Structure
8	 <chem>CCN1CC(=O)N(CC(=O)OC(C)(C)C)C1=O</chem>
9	 <chem>CCN1CC(=O)N(CC(=O)O)C1=O</chem>
10	 <chem>OC(=O)CC1=C(C(=O)O)C=CC=C1O</chem>